VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
VVN461,a non-steroidal dual JAK1/TYK2 immunomodulator,achieves primary endpoint,demonstrating statistical and clinical efficacy compared to vehicle in treatingpost-operative inflammation following cat









